B+
Bull case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
TARA
Protara TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Multiple late-stage programs provide several potential 4Q 2026 catalysts, while reported cash and investments of approximately $162 million are expected by management to support planned operations into 2028 [#SEC-8K-2026-08-11]. Successful enrollment, interim efficacy or safety data, and progress toward the planned LM BLA could re-rate the stock.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.7.
What can break
Clinical-stage cash burn, future financing, and dilution risk despite management's stated runway into 2028.
Momentum
13
Value
41
Sentiment
91
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.50 · Bull $7.50 · Bear $2.20Analysis 2026-09-03; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $25.71
Why
Momentum13 · Δ7d +1.9
Value41 · Δ7d -0.0
Sentiment91 · Δ7d +3.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +3.7.
Contradictions & invalidation
- • Clinical-stage cash burn, future financing, and dilution risk despite management's stated runway into 2028.
- • Delays, enrollment challenges, or unfavorable efficacy and safety data in ADVANCED-2, ADVANCED-3, STARBORN-1, or THRIVE-3.
- • The Q2 per-share loss reportedly missed consensus [#PR-EARNINGS-2026-08-11], and the investment case remains dependent on binary clinical and regulatory execution.
Catalyst clock
2026-09-30
Post-Q2 earnings digestion remains a near-term overhang
Lead driver: Sentiment · See AI snapshot
Momentum
13
9% active weight
Current posture
7d trendImproving
Δ7d
+1.9
Δ21d
-0.3
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
91
62% active weight
Current posture
7d trendImproving
Δ7d
+3.7
Δ21d
-9.5
Why this grade
Composite grade A. Momentum 13.2 / Value 41.2 / Sentiment 91.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-03. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$235.2M
Beta
1.37
Shares Out
59.1M
P/E (TTM) · Derived
-3.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.08
Rev YoY
-100.0%
EPS YoY
+0.4%
Gross Margin
-
Op Margin
-
Net Debt
-$152.2M
Current Ratio
10.97
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data